Government Weighs Keeping PBS Co-Payments at $25
Medicines Australia says patients are missing out on many new medicines available overseas.
Updated on Nov. 19, 2026 in Healthcare

Live Poll
Should the government spend more to bring new medicines to Australia?
The Australian government may keep co-payments for PBS-listed medicines at $25. Medicines Australia says as many as 200 medicines available overseas are not available in Australia.
Why it matters
Only 25 per cent of medicines launched globally over the past decade are listed on the PBS, and patients are waiting an average of 3.6 years for treatments already available overseas. The 2024 Review of the Health Technology Assessment process, which contains 50 recommendations, has not been acted on by the government.
Government spending on medicines as a share of GDP has fallen by 39 per cent since 2006, and spend per innovative script has dropped 28 per cent in five years. The extraction does not indicate how the government will respond to these declines.
The players
Medicines Australia
Medicines Australia is the peak industry body representing research-based pharmaceutical companies operating in Australia.
Elizabeth de Somer
Elizabeth de Somer is a public figure quoted in the debate over PBS listing and medicine access in Australia.
The details
Medicines Australia research found that only 25 per cent of medicines launched globally over the past decade are listed on the PBS, compared with 88 per cent approval in the United States. Insight Economics reported that PBS net spending has fallen as a share of GDP from 0.55 to 0.48 per cent between FY2016 and FY2026.
Timeline
FY2016: Net PBS spending share of the Health Budget begins its decline to 11 per cent by FY2026.
2024: The Review of the Health Technology Assessment process, with 50 recommendations, is released.
19 November 2026: Medicines Australia issues a statement on the $25 PBS pricing.
Market Landscape
The 2024 Review of the Health Technology Assessment process contains 50 recommendations that the government has not yet acted on. The continuing lag places Australia's PBS listing rate of 25 per cent well behind the 88 per cent approval rate in the United States.
If the $25 co-payment is maintained, patients will continue to pay that amount for PBS-listed medicines. Many medicines available overseas remain unavailable in Australia, so patients may keep waiting years for treatments.
The takeaway
Patients in Australia face long waits for medicines already approved overseas, so the pace of reform in listing decisions matters to everyday access. Watching whether the government acts on the 2024 Review's recommendations will show whether that wait shortens.
Further reading
Explore more on Healthcare coverage across Australia's medicine access and pricing policies.
More information
Read the Medicines Australia report on missing PBS medicines for the full figures.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should the government spend more to bring new medicines to Australia?






